PNC Financial Services Group’s 4D Molecular Therapeutics FDMT Stock Holding History

PNC Financial Services Group’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$19.7K	Sell	1,377 -105	-7%	-$1.37K	﹤0.01%	3868
2026 Q2	$19.7K	Buy	1,482 +20	+1%	+$195	﹤0.01%	3788
2026 Q1	$13.6K	Sell	1,462 -5,713	-80%	-$49.7K	﹤0.01%	3847
2025 Q4	$53.8K	Sell	7,175 -131	-2%	-$1.33K	﹤0.01%	3171
2025 Q3	$63.5K	Sell	7,306 -1,854	-20%	-$11.1K	﹤0.01%	3065
2025 Q2	$34K	Buy	9,160 +1,257	+16%	+$4.42K	﹤0.01%	3326
2025 Q1	$25.5K	Sell	7,903 -1,221	-13%	-$5.75K	﹤0.01%	3430
2024 Q4	$50.8K	Buy	9,124 +3,630	+66%	+$28.5K	﹤0.01%	3097
2024 Q3	$59.4K	Buy	5,494 +1,134	+26%	+$18.8K	﹤0.01%	2989
2024 Q2	$91.5K	Buy	4,360 +4,332	+15,471%	+$109K	﹤0.01%	2687
2024 Q1	$892	Sell	28 -4	-13%	-$102	﹤0.01%	4386
2023 Q4	$648	Buy	+32	New	+$421	﹤0.01%	4372

Other funds holding FDMT

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

PNC Financial Services Group's FDMT Position: Q3 2026 in Review

PNC Financial Services Group reduced its 4D Molecular Therapeutics (FDMT) stake by 7.1% in Q3 2026, selling an estimated $1.37K and leaving 1,377 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3868.

PNC Financial Services Group first reported a position in FDMT in Q4 2023 and has held it in 12 quarters since. The position peaked at $91.5K in Q2 2024. 87 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

PNC Financial Services Group held 1,377 shares of 4D Molecular Therapeutics worth $19.7K as of Q3 2026.
PNC Financial Services Group sold 105 4D Molecular Therapeutics shares in Q3 2026, an estimated $1.37K.
4D Molecular Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3868 holding.
PNC Financial Services Group first reported a position in 4D Molecular Therapeutics in Q4 2023 and has held it in 12 quarters since.
PNC Financial Services Group's 4D Molecular Therapeutics position peaked at $91.5K in Q2 2024.
87 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.